These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37721754)
1. Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. Boige V; Blons H; François E; Ben Abdelghani M; Phelip JM; Le Brun-Ly V; Mineur L; Galais MP; Villing AL; Hautefeuille V; Miglianico L; De La Fouchardière C; Genet D; Levasseur N; Levaché CB; Penel N; Mitry E; Jacquot S; Aparicio T; Brument E; Gourgou S; Castan F; Bouché O JAMA Netw Open; 2023 Sep; 6(9):e2333533. PubMed ID: 37721754 [TBL] [Abstract][Full Text] [Related]
2. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
3. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072 [TBL] [Abstract][Full Text] [Related]
4. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related]
5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968 [TBL] [Abstract][Full Text] [Related]
6. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial. Wang L; Liu Y; Yin X; Fang W; Xiong J; Zhao B; Zhang M; Zou Y; Qiu H; Yuan X JAMA Netw Open; 2020 Jul; 3(7):e2011036. PubMed ID: 32687588 [TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570 [TBL] [Abstract][Full Text] [Related]
8. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. Pietrantonio F; Morano F; Corallo S; Miceli R; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Bergamo F; Sartore-Bianchi A; Tampellini M; Racca P; Clavarezza M; Berenato R; Caporale M; Antista M; Niger M; Smiroldo V; Murialdo R; Zaniboni A; Adamo V; Tomasello G; Giordano M; Petrelli F; Longarini R; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; de Braud F JAMA Oncol; 2019 Sep; 5(9):1268-1275. PubMed ID: 31268481 [TBL] [Abstract][Full Text] [Related]
9. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865 [TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for Pinto C; Orlandi A; Normanno N; Maiello E; Calegari MA; Antonuzzo L; Bordonaro R; Zampino MG; Pini S; Bergamo F; Tonini G; Avallone A; Latiano TP; Rosati G; Cogoni AA; Ballestrero A; Zaniboni A; Roselli M; Tamberi S; Barone C J Clin Oncol; 2024 Apr; 42(11):1278-1287. PubMed ID: 38181312 [TBL] [Abstract][Full Text] [Related]
11. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial. Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721 [TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. Yasui H; Okita Y; Nakamura M; Sagawa T; Watanabe T; Kataoka K; Manaka D; Shiraishi K; Akazawa N; Okuno T; Shimura T; Shiozawa M; Sunakawa Y; Ota H; Kotaka M; Okuyama H; Takeuchi M; Ichikawa W; Fujii M; Tsuji A ESMO Open; 2023 Oct; 8(5):101636. PubMed ID: 37703596 [TBL] [Abstract][Full Text] [Related]